Forskare vid Institutionen för immunologi, genetik och patologi, Cancerprecisionsmedicin; Forskargrupp Tobias Sjöblom
- Dag Hammarskjölds väg 20
751 37 Uppsala
751 85 Uppsala
2020.02 – Present, Researcher/Project leader in Department of Immunology, Genetics and Pathology, Uppsala University. Main research focus: Finding and understanding mutations that cause cancer and pursue novel cancer therapeutic strategies by targeting cancer-specific vulnerabilities in cell-cycle inactive cancer cell populations.
2019.01 – 2020.02, Visiting researcher in Department of Obstetrics, Gynaecology and Women's Health, University of Minnesota, USA. Main research focus: Targeting metabolism variations in ovarian carcinoma in metabolically compromised 3D microenvironments.
2015.08 – 2019.01, Post-doctoral fellow at Karolinska Institute, Sweden / Linkoping University, Sweden. Main research focus: Developing efficient strategies for cancer treatments by modulating redox pathways in tumour.
2023-2025, Swedish Childhood Cancer Project Fund.
2023-2024, Lena Wäppling's Fund.
2022-2025, Göran Gustafssons Stiftelse's large prize fund on Medicine, Sweden.
2022-2024, Jeanssons Stiftelse Grant, Sweden.
2021-2025, Research position (Forskarassistent) with 4-year research funding, Swedish Childhood Cancer Fund.
Swedish Childhood Cancer Fund.
Robert Lundbergs Fund.
2011-2015, Ph.D at Department of Oncology-Pathology / Cancer Centre Karolinska, Karolinska Institute, Sweden.
2008-2010, M.Sc in Biomedicine, Chalmers University of Technology, Gothenburg, Sweden
Course leader in Master programme of Forensic Medicine, Uppsala University, Sweden
My research focuses on exploring the unique features of quiescent tumor cells that are resistant to conventional anticancer treatments, specifically the mitochondria. By studying these features, I hope to develop more effective therapeutic strategies for clinical treatment
Specific topics I am working with:
1. The mutations in mitochondria affect the quiescent cell populations in solid tumours (CRC and neuroblastoma) during tumorigenesis.
2. Drug screening to identify novel chemicals target MYCN-amplificated neuroblastoma in 3D based tumour model, targets of the novel drug candidate, MYCN independence.
3. Identification and confirmation of novel targets under LOH process in CRC and Neuroblastoma, autophagy reaction under certain mitochondrial inhibition, the vulnerabilities related to autophagy for the treatment of neuroblastoma.
Here is my main Publication list.
Kontakta katalogansvarig vid den aktuella organisationen (institution eller motsv.) för att rätta ev. felaktigheter.